Journals / Gülhane Tıp Dergisi / 2010 / Cilt: 52 - Sayı: 1

Ruptured endometrioma and high levels of tumor markers: A case report

Rüptüre endometriyoma ve yüksek serum tümör belirteçleri: Olgu sunumu

Pages
49–51
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The case emphasizes that high levels of CA 125 and 19-9 may also be encountered in benign gynecologic conditions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:CA 125 is a tumor-associated antigen.
📊
Key Findings & Data:Its high levels are usually associated with ovarian malignancies, however increases in its levels may also be encountered in benign gynecologic conditions.
💡
Conclusion & Impact:The case emphasizes that high levels of CA 125 and 19-9 may also be encountered in benign gynecologic conditions.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

CA 125 is a tumor-associated antigen. Its high levels are usually associated with ovarian malignancies, however increases in its levels may also be encountered in benign gynecologic conditions. Patients with endometriosis have rarely a serum CA 125 concentration exceeding 100 IU/ml. In this article a high level of CA 125 in a case of large ruptured ovarian endometrioma is reported. A 20-year-old nulligravida woman presented with an abdominal pain lasting for 8 hours. Transabdominal ultrasonography demonstrated bilaterally large endometriomas, and serum CA 125 and CA 19-9 levels were detected as 3434 U/ml and 1175 U/ml, respectively. Exploratory laparatomy was performed, and two endometrioma cysts with a diameter of 15 cm and 12 cm in the right and left overs, respectively, were excised. The diagnosis was confirmed histopathologically. The serum CA 125 and 19-9 levels tended to decrease in 8 weeks and declined to normal levels in 16 weeks. CA 125 and 19-9 are usually associated with a malignant process. However they may also increase in benign conditions such as a ruptured endometrioma. The case emphasizes that high levels of CA 125 and 19-9 may also be encountered in benign gynecologic conditions.

Özet

CA 125 tümörlerle ilişkili bir antijendir. Genelde ovaryan malignitelerde yüksek seviyelerde tespit edilir, ancak benign jinekolojik patolojilerde de serumda artmış olarak bulunabilir. Endometriyozisli hastalarda serumdaki seviyesi nadiren 100 U/ml'yi geçer. Bu makalede rüptüre olmuş büyük endometriyomalı bir hastada yüksek seviyede tespit edilen CA 125 seviyesi rapor edilmiştir. Yirmi yaşında nulligravid bir hasta 8 saattir devam eden karın ağrısı şikayeti ile başvurdu. Transabdominal ultrasonografide bilateral büyük ovaryan endometriyoma saptandı ve serum CA 125 seviyesi 3434 U/ml ve CA 19-9 ise 1175 U/ml olarak tespit edildi. Eksploratris laparatomi yapılan hastada sağ ovaryan 15 cm, sol ovaryan 12 cm boyutunda endometriyoma kistleri eksize edildi. Histopatolojik olarak tanı doğrulandı. Sekiz hafta içerisinde serum CA 125 ve 19-9 seviyeleri azalarak, 16 hafta içerisinde normal seviyelere geriledi. CA 125 ve 19-9 genelde malign durumlarla ilişkilidir. Ancak rüptüre endometriyoma gibi benign durumlarda da yüksek seviyelerde tespit edilebilir. Bu olgu benign jinekolojik patolojilerde yüksek CA 125 ve 19-9 düzeyleri ile karşılaşabileceğimizi vurgulamaktadır.

🔖

Cite This Article

ALANBAY, İ., KARAŞAHİN, K. E., ERCAN, C. M., FİDAN, U., DEDE, M., YENEN, M. C. (2010). Ruptured endometrioma and high levels of tumor markers: A case report. Gülhane Tıp Dergisi, Cilt: 52 - Sayı: 1, 49–51. https://ajindex.com/articles/225448

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Johansson J, Santala M, Kauppila A. Explosive rise of serum CA 125 following the rupture of ovarian endometrioma. Hum Reprod 1998; 13: 3503-3504
  2. Matalliotakis I, Panidis D, Vlassis G, Neonaki M, Goumenou A, Koumantakis E. Unexpected increase of the CA 19-9 tumour marker in patients with endometriosis. Eur J Gynaecol Oncol 1998; 19: 498-500
  3. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312
  4. Davis L, Kennedy SS, Moore J, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007; 18: CD001019
  5. Tsikouras T, Liberis V, Galazios G, Sarri S, Teichmann AT. Contribution of laparoscopy in young women with abdominal pain. Clin Exp Obstet Gynecol 2007; 34: 168-170
  6. Dede M, Gungor S, Yenen MC, Alanbay I, Duru NK, Haşimi A. CA19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer 2006; 16: 189-193
  7. O’Shaughnessy A, Check JH, Nowroozi K, Lurie D. CA 125 levels measured in different phases of the menstrual cycle in screening for endometriosis. Obstet Gynecol 1993; 81: 99-103
  8. Barbieri RL. CA 125 in patients with endometriosis. Fertil Steril 1986; 45: 767-769
  9. Koninckx PR, Riittinen L, Seppala M, Cornillie FJ. CA 125 and placental protein 14 concentrations in plasma and peritoneal fluid of women with deeply infiltrating pelvic endometriosis. Fertil Steril 1992; 57: 523-530
  10. Yedema CA, Kenemans P, Voorhorst F, et al. CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993; 67: 1361-1367
  11. Gungor S, Dede M, Baser I, Yenen MC, Goktolga U. Ruptured endometrioma with a serum CA 125 level of 3137 IU/ml: a case report. Gynecol Obstet Reprod Med 2003; 9: 216-218.